GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

Cytokinetics has shared positive top-line results from a late-stage study of its investigational oral cardiac myosin ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Pharma marketers are embracing chat-based tools to engage HCPs and patients faster, simplify PI sharing, and gain real-time ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

We can’t talk about challenges to women’s reproductive health without acknowledging that we’re living in unprecedented times, ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast ...

Johnson & Johnson (J&J) has announced that its bladder cancer therapy Balversa (erdafitinib) has been accepted by the ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and ...

The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

Takeda’s Adzynma (rADAMTS13) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat ...